An observational study in Cerebral Small Vessel Disease, sponsored by Ruijin Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by Ruijin Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Cerebral Small Vessel Diseases with a site in China — 32 open to participants now, 33 under way, 1 of them phase 3. Cerebral Small Vessel Diseases · China.
Among the 48 studies in Cerebral Small Vessel Diseases with a site in China, this one is the 13th largest by planned enrollment of the 22 observational ones that give a count, is one of 5 that started in 2026, is one of 22 observational ones, reaches primary completion later than 21 of the 32 other live ones, and was the 47th registered.
128 studies on the registry are indexed under Cerebral Small Vessel Diseases; 71 are open to participants now.
Browse Cerebral Small Vessel Diseases studies →32 of the 48 studies in Cerebral Small Vessel Diseases with a site in China are open now. Recruiting first, the newest first:
Dongzhimen Hospital, Beijing · Sites in China
Ages 50+
Peking Union Medical College Hospital · Sites in China
Ages 30–80
Beijing Tiantan Hospital · Sites in China
Ages 45–80
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 30–79
Beijing Tiantan Hospital · Sites in China
Ages 50–75 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 46 Cerebral Small Vessel Diseases studies recruiting now, 26 (57%) set no upper age limit and 5 (11%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 260 across 56 observational studies indexed under Cerebral Small Vessel Diseases.
Median enrollment 105 across the 26 interventional studies, 749 across the 22 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 48 has an industry lead sponsor. The 10 most frequent:
Ruijin Hospital is the lead sponsor of 679 studies on the registry; 387 are open to participants now.
Ruijin Hospital has 1 study filed under Cerebral Small Vessel Diseases — fewer than ten, so there is no comparison to draw.
8 of the studies in Cerebral Small Vessel Diseases with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06674460Phase 3Peking Union Medical College HospitalTreatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease | 2027-10-01 |
| NCT07317557Jiangsu Province Nanjing Brain HospitalRemote Ischemic Conditioning for Cognitive Impairment in Cerebral Small Vessel Disease | 2026-12-31 |
| NCT07271732Dongzhimen Hospital, BeijingSongling Xuemaikang Capsules for Cerebral Small Vessel Disease | 2026-12-31 |
| NCT05356104Chinese University of Hong KongGLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) | 2027-05 |
| NCT06512376Beijing Tiantan HospitalHereditary Cerebral Small Vessel Diseases Registry-Trial Ready Cohort | 2027-07-19 |
Add all 8 to your calendar (.ics) → With an account.
Among the 48 studies in Cerebral Small Vessel Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about neuroimage and biomarkers in the cerebral small vessel disease. The main questions it aims to answer are:
This observational study recruits participants with cerebral small vessel disease (CSVD) from hospitals and community-based populations. Healthy volunteers will also be recruited as controls. Longitudinal follow-up of these participants will help clarify the significance of neuroimaging and biological biomarkers during the development and progression of CSVD.
The investigators aim to establish a longitudinal cohort covering the spectrum of CSVD and identify key biomarkers associated with disease progression and cognitive decline. All participants will undergo multimodal MRI, PET imaging (optional) with different tracers, and blood biomarker assessments. Using multimodal MRI, the investigators will investigate alterations in neurovascular coupling and their role in the pathophysiology of CSVD. In addition, PET imaging (optional) and blood biomarkers will be used to characterize the spatial and temporal patterns of disease-related biomarker changes. Furthermore, additional neuroimaging and digital biomarkers will be evaluated within the cohort to improve disease characterization and prognostic prediction.
The population consists of vascular dementia, vascular mild cognitive impairment, and cognitively normal participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Evidence of cerebral small vessel disease (CSVD) on brain MRI, meeting at least one of the following imaging criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants do not have cognitive impairment.
Participants have vascular cognitive impairment, but no cognitive impairment
Participants have vascular cognitive impairment or difficulty in daily activity.
Global cognitive ability
Mini-mental state examination
Time frame: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Executive function
Clock drawing test
Time frame: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Visual memory
Rey-Osterich complex figure test
Time frame: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Short-term memory
Auditory verbal learning test
Time frame: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Executive memory
Symbol-digit test
Time frame: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Spatial executive function
Trail making test
Time frame: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Naming ability
Boston naming test
Time frame: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Language ability
Language fluency test
Time frame: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Sleep quality
Sleep disorder
Time frame: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Movement ability
Part III of the Unified Parkinson's Disease Rating Scale
Time frame: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Brain volume
Annual changes of volumes of brain
Time frame: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Connectivity integrity of the neural circuit
Annual changes of hippocampus related neural connectivity
Time frame: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Volume of white matter lesions
Structural and functional MRI measures, including arterial spin labeling (ASL), diffusion MRI (dMRI), susceptibility-weighted imaging (SWI) and fluid-attenuated inversion recovery (FLAIR).
Time frame: baseline, 1 year, 2-year, 3-year, 5-year,10-year
Plan to share: Undecided — There is not yet a plan to make IPD available to other researchers
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Sep 2028, 26 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cerebral Small Vessel Diseases →